Literature DB >> 12598911

Immunohistochemical markers of melanocytic tumors.

Hadi Yaziji1, Allen M Gown.   

Abstract

While historically detection of premelanosomes by electron microscopic studies was the only means possible of confirming melanocytic lineage of a neoplastic process, advances in the field of immunohistochemistry have allowed for accurate and reliable diagnosis using antibodies to 1 of a number of melanocyte-restricted proteins. S-100 was the first such marker exploited by immunohistochemistry; subsequently, the HMB45 monoclonal antibody to gp100 became widely used as a sensitive and specific melanocytic marker. More recently, antibodies to other melanocytic proteins have become available, inciuding the MART-1 gene product and microphthalmia transcription factor. This article provides a brief overview of these markers in terms of their specificity and sensitivity and offers a discussion of tumors with partial melanocytic differentiation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12598911     DOI: 10.1177/106689690301100103

Source DB:  PubMed          Journal:  Int J Surg Pathol        ISSN: 1066-8969            Impact factor:   1.271


  10 in total

1.  SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions.

Authors:  Ferdinando Pucci; Christopher Garris; Charles P Lai; Andita Newton; Christina Pfirschke; Camilla Engblom; David Alvarez; Melissa Sprachman; Charles Evavold; Angela Magnuson; Ulrich H von Andrian; Katharina Glatz; Xandra O Breakefield; Thorsten R Mempel; Ralph Weissleder; Mikael J Pittet
Journal:  Science       Date:  2016-03-17       Impact factor: 47.728

2.  Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2.

Authors:  Francesca Avogadri; Sacha Gnjatic; Jodie Tassello; Denise Frosina; Nicole Hanson; Megan Laudenbach; Erika Ritter; Taha Merghoub; Klaus J Busam; Achim A Jungbluth
Journal:  Am J Dermatopathol       Date:  2016-03       Impact factor: 1.533

Review 3.  Cutaneous Melanomas: A Single Center Experience on the Usage of Immunohistochemistry Applied for the Diagnosis.

Authors:  Costantino Ricci; Emi Dika; Francesca Ambrosi; Martina Lambertini; Giulia Veronesi; Corti Barbara
Journal:  Int J Mol Sci       Date:  2022-05-25       Impact factor: 6.208

4.  Extramammary Paget's disease in Korea: its association with gastrointestinal neoplasms.

Authors:  Sang Nam Yoon; In Ja Park; Hee Cheol Kim; Chang Sik Yu; Mi Woo Lee; Jai Kyoung Koh; Jin Wou Kim; Young Soo Park; Jin Cheon Kim
Journal:  Int J Colorectal Dis       Date:  2008-06-06       Impact factor: 2.571

5.  Malignant peripheral nerve sheath tumour-like primary cutaneous malignant melanoma.

Authors:  J Cruz; J S Reis-Filho; J M Lopes
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

6.  Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.

Authors:  Bonnie E Gould Rothberg; Christopher B Moeder; Harriet Kluger; Ruth Halaban; David E Elder; George F Murphy; Alexander Lazar; Victor Prieto; Lynn McDivitt Duncan; David L Rimm
Journal:  Mod Pathol       Date:  2008-06-13       Impact factor: 7.842

7.  PMEL as a Prognostic Biomarker and Negatively Associated With Immune Infiltration in Skin Cutaneous Melanoma (SKCM).

Authors:  Shuguang Zhang; Kun Chen; Huanmei Liu; Changyou Jing; Xinxin Zhang; Chunfeng Qu; Shengji Yu
Journal:  J Immunother       Date:  2021 Jul-Aug 01       Impact factor: 4.456

8.  Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma.

Authors:  Harish Potu; Luke F Peterson; Malathi Kandarpa; Anupama Pal; Hanshi Sun; Alison Durham; Paul W Harms; Peter C Hollenhorst; Ugur Eskiocak; Moshe Talpaz; Nicholas J Donato
Journal:  Nat Commun       Date:  2017-02-15       Impact factor: 14.919

9.  p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis.

Authors:  Rubeta N Matin; Anissa Chikh; Stephanie Law Pak Chong; David Mesher; Manuela Graf; Paolo Sanza'; Valentina Senatore; Maria Scatolini; Francesca Moretti; Irene M Leigh; Charlotte M Proby; Antonio Costanzo; Giovanna Chiorino; Rino Cerio; Catherine A Harwood; Daniele Bergamaschi
Journal:  J Exp Med       Date:  2013-02-18       Impact factor: 14.307

10.  Metastatic malignant melanoma in bone marrow with occult primary site--a case report with review of literature.

Authors:  Deepali Jain; Tejindar Singh; Naresh Kumar; Mradul K Daga
Journal:  Diagn Pathol       Date:  2007-10-02       Impact factor: 2.644

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.